TY - JOUR
T1 - Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction
AU - Hartog, Jasper W. L.
AU - van de Wal, Ruud M.
AU - Schalkwijk, Casper G.
AU - Miyata, Toshio
AU - Jaarsma, Wybren
AU - Plokker, H. W. Thijs
AU - van Wijk, Leen M.
AU - Smit, Andries J.
AU - van Veldhuisen, Dirk J.
AU - Voors, Adriaan A.
PY - 2010/4
Y1 - 2010/4
N2 - Aims To investigate the relationship between advanced glycation end-products (AGEs) and diastolic function and the response to blood pressure treatment in patients with hypertension and diastolic dysfunction. Methods and results Data were analysed from 97 patients (aged 65 +/- 10 years, 36% male) who were randomly assigned to 6 months open-label treatment with either eprosartan on top of other anti-hypertensive drugs (n = 47) or other antihypertensive drugs alone (n = 50). Tissue AGE accumulation was measured using a validated skin-autofluorescence (skin-AF) reader (n = 26). Plasma N(epsilon)-(carboxymethyl) lysine (CML), N(epsilon)-(carboxyethyl) lysine (CEL), and pentosidine were measured by LC-MS/MS and HPLC. Diastolic function was assessed using echocardiography. Blood pressure was reduced from 157/91 to 145/84 mmHg (P median, E/A ratio (P = 0.84) and mean E' (P = 0.32) remained unchanged. Conclusion Although eprosartan did not decrease levels of AGEs, patients with lower skin-AF at baseline showed a larger improvement in diastolic function in response to either anti-hypertensive treatment compared with patients with higher skin-AF.
AB - Aims To investigate the relationship between advanced glycation end-products (AGEs) and diastolic function and the response to blood pressure treatment in patients with hypertension and diastolic dysfunction. Methods and results Data were analysed from 97 patients (aged 65 +/- 10 years, 36% male) who were randomly assigned to 6 months open-label treatment with either eprosartan on top of other anti-hypertensive drugs (n = 47) or other antihypertensive drugs alone (n = 50). Tissue AGE accumulation was measured using a validated skin-autofluorescence (skin-AF) reader (n = 26). Plasma N(epsilon)-(carboxymethyl) lysine (CML), N(epsilon)-(carboxyethyl) lysine (CEL), and pentosidine were measured by LC-MS/MS and HPLC. Diastolic function was assessed using echocardiography. Blood pressure was reduced from 157/91 to 145/84 mmHg (P median, E/A ratio (P = 0.84) and mean E' (P = 0.32) remained unchanged. Conclusion Although eprosartan did not decrease levels of AGEs, patients with lower skin-AF at baseline showed a larger improvement in diastolic function in response to either anti-hypertensive treatment compared with patients with higher skin-AF.
KW - Hypertension
KW - Advanced glycation end-products
KW - Diastolic function
KW - Skin-autofluorescence
KW - Tissue velocity imaging
U2 - 10.1093/eurjhf/hfq001
DO - 10.1093/eurjhf/hfq001
M3 - Article
C2 - 20154337
SN - 1388-9842
VL - 12
SP - 397
EP - 403
JO - European journal of heart failure
JF - European journal of heart failure
IS - 4
ER -